Skip to content

Consistently reduced pupil size with steady increase in near vision acuity likely due to neuroadaptation1-3

 

DCNVA 20/40 or better (N=206)

Pupil Size vs. % Achieving 20/40 Vision or Better DCNVA OU

Dosing chart
Dosing chart

The Qlosi Clear Start Week

Help your patients achieve their near vision potential4

The Clear Start Week is for patients new to Qlosi and will help them adjust to their near vision. During this week, patients should be instructed to use Qlosi twice a day, every day. Consistent use at the start means the potential for better results over time as neuroadaptation takes effect.1-4

Flexible Dosing

Patients can now take advantage of the flexible dosing based on individual needs and can use Qlosi up to 2 times a day.4,*

*Presbyopia patients start with 1 drop of Qlosi in each eye twice a day for 7 days in a row.

See what resources are available to your patients

See patient support

Important Safety Information

Expand

Indication and Usage

 

Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

 

Important Safety Information

Contraindications

Hypersensitivity

 

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

 

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

 

Qlosi is not recommended to be used when iritis is present.

 

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi and wait 10 minutes before reinsertion.

 

Avoid touching the tip of the vial to the eye or any other surface.

 

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

 

Please see full Prescribing Information here: qlosi.com/prescribing-information

References
  1. Holland E, Karpecki P, Fingeret M, et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  2. Anderson RA, Cowle JB. Influence of pH on the effect of pilocarpine on aqueous dynamics. Br J Ophthalmol. 1968;52:607-611
  3. Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine. J Pharm Sci. 1988;77(9):771-775. doi:10.1002/jps.2600770911
  4. Qlosi [package insert]. Ponte Verda, FL. Orasis Pharmaceuticals.